نتایج جستجو برای: biomarker validation

تعداد نتایج: 227799  

2013
Raul Aguirre-Gamboa Hugo Gomez-Rueda Emmanuel Martínez-Ledesma Antonio Martínez-Torteya Rafael Chacolla-Huaringa Alberto Rodriguez-Barrientos José G. Tamez-Peña Victor Treviño

Validation of multi-gene biomarkers for clinical outcomes is one of the most important issues for cancer prognosis. An important source of information for virtual validation is the high number of available cancer datasets. Nevertheless, assessing the prognostic performance of a gene expression signature along datasets is a difficult task for Biologists and Physicians and also time-consuming for...

Journal: :Clinical chemistry 2013
Ziding Feng Jacob Kagan Margaret Pepe Mark Thornquist Jo Ann Rinaudo Jackie Dahlgren Karl Krueger Yingye Zheng Christos Patriotis Ying Huang Lynn Sorbara Ian Thompson Sudhir Srivastava

BACKGROUND The mission of the National Cancer Institute's Early Detection Research Network (EDRN) is to identify and validate cancer biomarkers for clinical use. Since its inception, EDRN investigators have learned a great deal about the process of validating biomarkers for clinical use. Translational research requires a broad spectrum of research expertise, and coordinating collaborative activ...

2017
David Petillo Stephen Orey Aik Choon Tan Lars Forsgren Sok Kean Khoo

Parkinson’s disease (PD) is the second most common neurodegenerative disease. One of the major challenges in studying this progressive neurological disorder is to identify and develop biomarkers for early detection. Recently, several blood-based microRNA (miRNA) biomarkers for PD have been reported. However, follow-up studies with new, independent cohorts have been rare. Previously, we identifi...

2004
Brian A. Stanley Rebekah L. Gundry Robert J. Cotter Jennifer E. Van Eyk

Heart disease is the leading cause of mortality and morbidity in the world. As such, biomarkers are needed for the diagnosis, prognosis, therapeutic monitoring and risk stratification of acute injury (acute myocardial infarction (AMI)) and chronic disease (heart failure). The procedure for biomarker development involves the discovery, validation, and translation into clinical practice of a pane...

2016
Janice M. Leung Virginia Chen Zsuzsanna Hollander Darlene Dai Scott J. Tebbutt Shawn D. Aaron Kathy L. Vandemheen Stephen I. Rennard J. Mark FitzGerald Prescott G. Woodruff Stephen C. Lazarus John E. Connett Harvey O. Coxson Bruce Miller Christoph Borchers Bruce M. McManus Raymond T. Ng Don D. Sin

BACKGROUND Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) result in considerable morbidity and mortality. However, there are no objective biomarkers to diagnose AECOPD. METHODS We used multiple reaction monitoring mass spectrometry to quantify 129 distinct proteins in plasma samples from patients with COPD. This analytical approach was first performed in a biomarker coh...

Journal: :Archives of neurology 2012
James D Doecke Simon M Laws Noel G Faux William Wilson Samantha C Burnham Chiou-Peng Lam Alinda Mondal Justin Bedo Ashley I Bush Belinda Brown Karl De Ruyck Kathryn A Ellis Christopher Fowler Veer B Gupta Richard Head S Lance Macaulay Kelly Pertile Christopher C Rowe Alan Rembach Mark Rodrigues Rebecca Rumble Cassandra Szoeke Kevin Taddei Tania Taddei Brett Trounson David Ames Colin L Masters Ralph N Martins

OBJECTIVE To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD). DESIGN Baseline plasma screening of 151 multiplexed analytes combined with targeted biomarker and clinical pathology data. SETTING General community-based, prospective, longitudinal study of aging. PARTICIPANTS A total of 754 healthy individuals serving as controls and 207 participants with AD from the Au...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006
Padma Maruvada Sudhir Srivastava

Cancer remains the second leading cause of death in the United States, in spite of tremendous advances made in therapeutic and diagnostic strategies. Successful cancer treatment depends on improved methods to detect cancers at early stages when they can be treated more effectively. Biomarkers for early detection of cancer enable screening of asymptomatic populations and thus play a critical rol...

Journal: :American journal of epidemiology 2011
Sarah Rosner Preis Donna Spiegelman Barbara Bojuan Zhao Alanna Moshfegh David J Baer Walter C Willett

Repeat-biomarker measurement error models accounting for systematic correlated within-person error can be used to estimate the correlation coefficient (ρ) and deattenuation factor (λ), used in measurement error correction. These models account for correlated errors in the food frequency questionnaire (FFQ) and the 24-hour diet recall and random within-person variation in the biomarkers. Failure...

Journal: :Clinical chemistry 2015
Xuemei Zhao Vijay Modur Leonidas N Carayannopoulos Omar F Laterza

BACKGROUND Biomarkers are important tools in drug development and are used throughout pharmaceutical research. CONTENT This review focuses on molecular biomarkers in drug development. It contains sections on how biomarkers are used to assess target engagement, pharmacodynamics, safety, and proof-of-concept. It also covers the use of biomarkers as surrogate end points and patient selection/com...

2011
Sarah Rosner Preis Donna Spiegelman Barbara Bojuan Zhao Alanna Moshfegh David J. Baer Walter C. Willett

Repeat-biomarker measurement error models accounting for systematic correlated within-person error can be used to estimate the correlation coefficient (q) and deattenuation factor (k), used in measurement error correction. These models account for correlated errors in the food frequency questionnaire (FFQ) and the 24-hour diet recall and random within-person variation in the biomarkers. Failure...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید